Novo Nordisk agrees weight loss price drop with US Administration
Denmark-based global chronic disease specialist Novo Nordisk has announced an agreement with the U.S. Administration to lower Wegovy and Ozempic prices across Medicare Part D, Medicaid and cash channels starting 2026. In exchange, Medicare will pilot obesity-drug coverage and the company gains a three-year tariff exemption. Management pegs the change at a low-single-digit drag on 2026 global sales growth but…